LUX-Lung IO: A phase II, open label, non-randomised study ofafatinib in combination with pembrolizumab in patients withlocally advanced or metastatic squamous cell carcinoma of thelung

  • STATUS
    Not Recruiting
  • sponsor
    Boehringer Ingelheim
Updated on 7 May 2021
cancer
squamous cell carcinoma
lung cancer
chemoradiotherapy
pembrolizumab
chemotherapy regimen
alopecia
afatinib
platinum-based chemotherapy
metastatic squamous cell carcinoma
lung carcinoma

Summary

LUX-Lung IO: A phase II, open label, non-randomised study of afatinib in combination with pembrolizumab in patients with locally advanced or metastatic squamous cell carcinoma of the lung

Description

This trial is an open-label, single arm phase II study assessing the tolerability and anti-tumour activity of afatinib when given in combination with a fixed dose of pembrolizumab in patients with squamous NSCLC, who progressed during or after first line platinum-based standard therapy and had no prior treatment with an immune checkpoint inhibitor or EGFR targeted therapy.
Benefits:
The patient’s condition may or may not improve if the patient joins this study. The patient may benefit from the patient’s tumor shrinking more and having a longer time before the tumor begins to grow again, but none of these benefits can be promised. The results of this study may help other people with the same condition in the future.

Details
Condition Squamous cell carcinoma, Lung Cancer
Clinical Study IdentifierTX153056
SponsorBoehringer Ingelheim
Last Modified on7 May 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note